# A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

> **NCT06909123** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Stanford University** · enrollment: 36 (estimated)

## Conditions studied

- Lactation Suppressed

## Interventions

- **DRUG:** Cabergoline

## Key facts

- **NCT ID:** NCT06909123
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-01
- **Final completion:** 2027-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909123, "A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06909123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*